Thus, to also explore the potential of HFn(DOX) as an innovative targeted nanodrug for the treatment of aggressive/metastatic breast cancer in pets, we moved forward to investigate the interaction of HFn with TFR-1 and the antitumor effect of HFn(DOX) in feline cell cultures. Here, TFRC is linked to breast carcinoma.